Your browser doesn't support javascript.
loading
Possible Efficacy of Vedolizumab, an Anti-α4ß7 Integrin Antibody, in Palmoplantar Pustulosis.
Terui, Hitoshi; Moroi, Rintaro; Masamune, Atsushi; Aiba, Setsuya; Yamasaki, Kenshi.
Affiliation
  • Terui H; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Moroi R; Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Masamune A; Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Aiba S; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Yamasaki K; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Case Rep Dermatol ; 15(1): 22-25, 2023.
Article in En | MEDLINE | ID: mdl-36726801
ABSTRACT
Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by vedolizumab (anti-α4ß7 integrin antibody) treatment for ulcerative colitis, suggesting the possibility of a new molecular target for PPP therapy.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Case Rep Dermatol Year: 2023 Document type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Case Rep Dermatol Year: 2023 Document type: Article Affiliation country: Japan